Investigator Initiated Study- Non-small cell lung cancer (NSCLC)

Lilly Oncology is dedicated to delivering innovative treatment approaches with the goal of improving the outcomes of people living with cancer. We are driven to accelerate the pace and progress of cancer care by developing a broad portfolio of therapies, including those tailored to unique patients and those that modulate the immune system. Lilly’s commitment to improving the length and quality of people’s lives is achieved through its internal drug development programs and its support of Investigator Initiated Research.

Therapeutic Area

Oncology

Region

USA

Submission Countdown

Days

Hours

In Scope:

Combinations: Generate efficacy and safety data of combinations of olomorasib and other agents in NSCLC
Monotherapy in patients with NSCLC (e.g., adjuvant treatment in patients ineligible for IO, treatment in patients who couldn’t tolerate prior G12Ci)
Response/resistance: Studies evaluating mechanisms of response and resistance to olomorasib

Out of Scope:

Olomorasib beyond the registrational dose (100mg BID)
Concepts that may pose a potential safety risk
Concepts that compete against ongoing or future Lilly-sponsored studies

PIRA™ suggested Proposal

PIRA™ proposals are AI generated and are not reviewed or endorsed by the sponsoring company.